** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences GILD.O lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.
** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEG
EXPECTING STRONG UPTAKE IN 2026
** J.P.Morgan ("overweight") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing
** Mizuho ("outperform", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers
** Oppenheimer ("outperform", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential
** TD Cowen ("buy", PT:$110) sees multi-billion dollar peak sales potential for Yeztugo and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。